448 results on '"Moriguchi, Michihisa"'
Search Results
2. Hepatocyte-specific GDF15 overexpression improves high-fat diet-induced obesity and hepatic steatosis in mice via hepatic FGF21 induction
3. Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database
4. Comparison of portal vein hemodynamics with ultrasound-based elastography for the prediction of liver fibrosis in patients with chronic liver disease
5. Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan
6. Honokiol Prevents Non-Alcoholic Steatohepatitis-Induced Liver Cancer via EGFR Degradation through the Glucocorticoid Receptor-MIG6 Axis.
7. Safety/efficacy of atezolizumab + bevacizumab during anti‐platelet/anticoagulation therapy in unresectable hepatocellular carcinoma
8. Re-administration of nivolumab after immune checkpoint inhibitor-induced cholangitis: the first reported case
9. Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice
10. The additive effect of genetic and metabolic factors in the pathogenesis of nonalcoholic fatty liver disease
11. Loss of KAP3 decreases intercellular adhesion and impairs intracellular transport of laminin in signet ring cell carcinoma of the stomach
12. Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents
13. Hepatocellular carcinoma diagnosis using a novel electrochemiluminescence immunoassay targeting serum IgM-free AIM
14. No lipiodol, no beads—another transcatheter arterial chemoembolization (TACE) with fine cisplatin powder and porous gelatin particles for TACE‐naïve, multifocal, up‐to‐seven out hepatocellular carcinoma.
15. Evolution of Systemic Treatment for Hepatocellular Carcinoma: Changing Treatment Strategies and Concepts.
16. A randomized, controlled trial of the efficacy of percutaneous transesophageal gastro-tubing (PTEG) as palliative care for patients with malignant bowel obstruction: the JIVROSG0805 trial
17. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study
18. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
19. Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database
20. MO7-6 Differences between tissue and blood specimens in CGP of pancreatic cancer from a real-world data of C-CAT
21. A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
22. Increase in the skeletal muscle mass to body fat mass ratio predicts the decline in transaminase in patients with nonalcoholic fatty liver disease
23. Correction to: Hepatocellular carcinoma diagnosis using a novel electrochemiluminescence immunoassay targeting serum IgM‑free AIM
24. Artificial intelligence/neural network system that accurately diagnoses hepatocellular carcinoma in nonalcoholic steatohepatitis
25. A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial
26. ASPP2 suppresses invasion and TGF-β1-induced epithelial–mesenchymal transition by inhibiting Smad7 degradation mediated by E3 ubiquitin ligase ITCH in gastric cancer
27. S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial
28. Loss of PAR-3 protein expression is associated with invasion, lymph node metastasis, and poor survival in esophageal squamous cell carcinoma
29. PPARα agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat
30. Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease
31. Gamma‐glutamyl transferase predicts pemafibrate treatment response in non‐alcoholic fatty liver disease
32. A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial
33. A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma potential in current real-world practice.
34. “Direct MPR”: A Useful Tool for Oblique CT Fluoroscopy-Assisted Puncture
35. Computed tomographic pulmonary angiography: Three cases of low-tube-voltage acquisition with a slow injection of contrast medium
36. Insulin resistance increases the risk of incident type 2 diabetes mellitus in patients with non‐alcoholic fatty liver disease
37. Hepatic nucleotide binding oligomerization domain‐like receptors pyrin domain‐containing 3 inflammasomes are associated with the histologic severity of non‐alcoholic fatty liver disease
38. Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma
39. Serum levels of immunoglobulin M‐free inhibitors of macrophage/CD5L as a predictive and early diagnostic marker for nonalcoholic steatohepatitis‐associated hepatocellular carcinoma
40. Real‐world outcomes of molecular targeted agents for patients with hepatocellular carcinoma over 80 years old
41. Effect of 12‐week dulaglutide therapy in Japanese patients with biopsy‐proven non‐alcoholic fatty liver disease and type 2 diabetes mellitus
42. Development of hepatocellular carcinoma in Japanese patients with biopsy‐proven non‐alcoholic fatty liver disease: Association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression
43. Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non‐alcoholic fatty liver disease and type 2 diabetes mellitus
44. Helicobacter pylori infection might have a potential role in hepatocyte ballooning in nonalcoholic fatty liver disease
45. Prospective Evaluation of the Optimal Duration of Bed Rest After Vascular Interventions Using a 3-French Introducer Sheath
46. Potential Therapeutic Targets and Promising Agents for Combating NAFLD
47. Transcatheter arterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable hepatocellular carcinoma (TACTICS-L) in Japan: Final analysis.
48. Clinical Practice Guidelines for Hepatic Arterial Infusion Chemotherapy with a Port System Proposed by the Japanese Society of Interventional Radiology and Japanese Society of Implantable Port Assisted Treatment
49. Honokiol Acts as a Potent Anti-Fibrotic Agent in the Liver through Inhibition of TGF-β1/SMAD Signaling and Autophagy in Hepatic Stellate Cells
50. Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.